TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

1.1121 Vincent JL. Drotrecogin alfa (activated) in the treatment of severe sepsis. Expert Rev Anti Infect
Ther 2006;4:537-47.
1.1122 Kreymann KG et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic
shock. Crit Care Med 2007;35:2677-85.
1.1123 Laupland KB et al. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and
septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35:
2686-92.
1.1124 Werdan K et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit
Care Med 2007;35:2693-701.
1.1125 Soylemez Wiener R et al. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.
J Am Med Assoc 2008;300:933-44.
1.1126 Finfer S et al. Tight glycemic control in critically ill adults. J Am Med Assoc 2008;300:963-5.
1.1127 COIITSS Study Investigators. Corticosteroid treatment and intensive insulin therapy for septic shock
in adults. A randomized controlled trial. J Am Med Assoc 2010;303:341-8.
1.1128 Brunkhorst FM et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl
J Med 2008;358:125-39.
1.1129 NICE-SUGAR investigators. Intensive versus conventional glucose control in critically ill patients. N
Engl J Med 2009;360:1283-97.
1.1130 Dellinger RP et al. Surviving Sepsis Campaign: international guidelines for management of severe
sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
1.1131 Dellinger RP et al. Surviving Sepsis Campaign: international guidelines for management of severe
sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60.
1.1132 Dellinger RP et al. Surviving Sepsis Campaign: international guidelines for management of severe
sepsis and septic shock: 2008. Intensive Care Med 2008;34:783-85.
1.1133 O‘Grady NO et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update
from the American College of Critical Care Medicine and the Infectious Diseases Society of America.
Crit Care Med 2008;36:1330-49.
1.1134 Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-713.
1.1135 Mackenzie I et al. Management of sepsis. Br Med J 2007;335:929-32.
1.1136 O‘Brien JM et al. Sepsis. Am J Med 2007;120:1012-22.
1.1137 Annane D et al. Septic shock. Lancet 2005;365:63-78.
1.1138 Sharma VK et al. Treatment options for severe sepsis and septic shock. Expert Rev Anti Infect Ther
2006;4:395-403.
1.1139 Hotchkiss RS et al. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
1.1140 Talan DA et al. Severe sepsis and septic shock in the emergency department. Infect Dis Clin North
Am 2008;22:1-31.
1.1141 Venkatesh MP et al. Management of neonatal sepsis by Gram-negative pathogens. Expert Rev Anti
Infect Ther 2008;6:929-38.
1.1142 Schrag SJ et al. Early-onset neonatal sepsis in the era of widespread intrapartum chemoprophylaxis.
Pediatr Infect Dis J 2006;25:939-40.
1.1143 Hart AC et al. Meningococcal disease and its management in children. Br Med J 2006;333:685-90.
1.1144 Stephens DS et al. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet
2007;369:2196-210.
1.1145 Hart AC et al. Meningococcal disease and its management in children. Br Med J 2006;333:685-90.
1.1146 Stephens DS et al. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet
2007;369:2196-210.
1.1147 Cunha BA. Fever of unknown origin: clinical overview of classic and current concepts. Infect Dis Clin
North Am 2007;21:867-915.
1.1148 Knockaert DC. Recurrent fevers of unknown origin. Infect Dis Clin North Am 2007;21:1189-211.
1.1149 Hughes WT et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Clin Infect Dis 2002;34:730-51.
1.1150 Marti Marti F et al. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol
2009;20(suppl. 4):iv166-69.
1.1151 Smith TJ et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based
clinical practice guideline. J Clin Oncol 2006;24:3187-205.
1.1152 Cometta A et al. Empirical use of anti-Gram-positive antibiotics in febrile neutropenic cancer patients
with acute leukaemia. Eur J Cancer Suppl 2007;5:23-31.
1.1153 Antoniadou A et al. Fever of unknown origin in febrile leukopenia. Infect Dis Clin North Am 2007;21:
1055-90.
1.1154 Aoun M. Empiric therapy for febrile neutropenia: what are the choices? Expert Rev Anti Infect Ther
2007;5:507-15.
1.1155 Castagnola E et al. Management of bacteremia in patients undergoing hematopoietic stem cell transplantation.
Expert Rev Anti Infect Ther 2009;7:607-21.
1.1156 Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009;101
(suppl. 1):S18-22.
1.1157 Meckler G et al. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin North Am
2009;27:525-44.
1.1158 Ellis M. Febrile neutropenia. Ann NY Acad Sci 2008;1138:329-350.
1.1159 Attygalle D et al. New trends in the management of tetanus. Expert Rev Anti Infect Ther 2004;2:73-
84.
1.1160 Brook I. Current concepts in the management of Clostridum tetani infection. Expert Rev Anti Infect
Ther 2008;6:327-36.
1.1161 Ahmadsyah I et al. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin
and metronidazole. Br Med J 1985;291:648-50.
1.1162 Kabura L et al. Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or
equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Health 2006;11:
1075-81.
1.1163 Lappin E et al. Gram-positive toxic shock syndromes. Lancet Infect Dis 2009;9:281-90.
1.1164 Fischer M et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion.
N Engl J Med 2005;353:2352-60.
1.1165 Sinave C et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion
disease. Clin Infect Dis 2002;35:1441-3.